Ascletis Begins Phase Two Diabetes Drug Trial
January 26, 2026 | 11:40
The biopharmaceutical company commenced dosing patients in its thirteen-week American clinical study evaluating an oral GLP-1 receptor agonist for diabetes management.
VinFuture Laureate Prof. Drucker Sees More Innovation Ahead in GLP-1 Therapies
April 14, 2025 | 22:00
Prof. Daniel Drucker’s pioneering work on GLP-1, in collaboration with world-renowned scientists, has transformed treatment for diabetes and obesity - and is now opening new frontiers in neurodegenerative disease research.
Mobile Version